down arrow

STERIS Plc (Ireland)

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IE00BFY8C754
USD
259.52
-1.38 (-0.53%)

Jan 23

NYS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

255.95259.65

52 Week

204.90269.23
Valuation
Technical
Day's Volume

CASH

138.98 k

Shareholding (Sep 2025)

FII

32.38%

Held by 298 FIIs

DII

29.59%

Held by 50 DIIs

Promoter

0.01%

How big is STERIS Plc (Ireland)?

22-Jun-2025

As of Jun 18, STERIS Plc (Ireland) has a market capitalization of 23,321.79 million, with net sales of 5,459.51 million and a net profit of 611.56 million reported for the latest four quarters.

Market Cap: As of Jun 18, STERIS Plc (Ireland) has a market capitalization of 23,321.79 million, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, STERIS Plc reported net sales of 5,459.51 million and a net profit of 611.56 million.<BR><BR>Balance Sheet Snapshot: As of Mar 25, the company reported shareholder's funds of 6,603.40 million and total assets of 10,146.81 million.

View full answer

What does STERIS Plc (Ireland) do?

22-Jun-2025

STERIS Plc (Ireland) provides infection prevention and procedural products and services in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $1.481 billion and a net profit of $147 million, with a market cap of approximately $23.32 billion.

Overview: <BR>STERIS Plc (Ireland) is a provider of infection prevention and procedural products and services in the Pharmaceuticals & Biotechnology industry, categorized as a large-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,481 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 147 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 23,321.79 Million (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 34.00 <BR>Dividend Yield: 0.96% <BR>Debt Equity: 0.29 <BR>Return on Equity: 10.94% <BR>Price to Book: 3.53<BR><BR>Contact Details: <BR>Address: Block a Riverside IV, 70 Sir John Rogerson's Quay DUBLIN None : 2 <BR>Tel: ['353 1 2322000', '1 440 3927245'] <BR>Website: https://www.steris.com/

View full answer

Who are in the management team of STERIS Plc (Ireland)?

22-Jun-2025

As of March 2022, the management team of STERIS Plc (Ireland) includes Dr. Mohsen Sohi (Independent Chairman), Mr. Walter Rosebrough (President and CEO), and several independent directors: Mr. Richard Breeden, Ms. Cynthia Feldmann, Dr. Jacqueline Kosecoff, Mr. Christopher Holland, and Mr. David Lewis.

As of March 2022, the management team of STERIS Plc (Ireland) includes the following individuals:<BR><BR>- Dr. Mohsen Sohi, Independent Chairman of the Board<BR>- Mr. Walter Rosebrough, President, Chief Executive Officer, Director<BR>- Mr. Christopher Holland, Director<BR>- Mr. Richard Breeden, Independent Director<BR>- Ms. Cynthia Feldmann, Independent Director<BR>- Dr. Jacqueline Kosecoff, Independent Director<BR>- Mr. David Lewis, Independent Director

View full answer

Is STERIS Plc (Ireland) overvalued or undervalued?

20-Sep-2025

As of August 7, 2025, STERIS Plc is considered overvalued with a P/E ratio of 34, an EV to EBITDA ratio of 17.51, and a PEG ratio of 1.28, despite recent strong performance, as its long-term returns lag behind the S&P 500.

As of 7 August 2025, the valuation grade for STERIS Plc (Ireland) has moved from fair to expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 34, which is significantly higher than the industry average, and an EV to EBITDA ratio of 17.51, further supporting the notion of overvaluation. Additionally, the PEG ratio stands at 1.28, suggesting that the stock price may not be justified by its growth prospects.<BR><BR>In comparison to its peers, STERIS Plc's P/E ratio is higher than Edwards Lifesciences Corp. at 31.17 and lower than ResMed, Inc. at 37.73, while its EV to EBITDA ratio is lower than that of Edwards Lifesciences Corp. at 26.51. The company's recent stock performance shows a year-to-date return of 21.86%, which outpaces the S&P 500's 12.22%, but over the longer term, its 3-year and 5-year returns of 29.31% and 42.40% respectively lag behind the S&P 500's 70.41% and 96.61%. This suggests that while STERIS has performed well recently, its valuation may not be sustainable in the long run.

View full answer

Is STERIS Plc (Ireland) technically bullish or bearish?

06-Oct-2025

As of October 3, 2025, STERIS Plc's technical trend is mildly bullish, supported by positive MACD and KST indicators, though it has underperformed the S&P 500 recently while outperforming it year-to-date, indicating mixed signals that suggest caution.

As of 3 October 2025, the technical trend for STERIS Plc (Ireland) has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the monthly MACD and KST also remain bullish. The Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames. However, the Dow Theory shows a mildly bearish signal on the weekly chart, contrasting with a mildly bullish monthly outlook. The daily moving averages are mildly bullish. <BR><BR>In terms of performance, STERIS has underperformed the S&P 500 over the past week and month, with returns of -2.64% and 0.02% respectively, while the S&P 500 returned 1.09% and 4.15%. However, year-to-date, STERIS has outperformed the S&P 500 with a return of 17.97% compared to 14.18%. Overall, the current technical stance is mildly bullish, but with some mixed signals indicating caution.

View full answer

Compare STERIS Plc (Ireland) with Similar Stocks

ResMed, Inc.Align Technology, Inc.Zimmer Biomet Holdings, Inc.
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 9.63

 
2

Healthy long term growth as Net Sales has grown by an annual rate of 13.16% and Operating profit at 12.29%

 
3

The company has declared Positive results for the last 4 consecutive quarters

4

With ROCE of 11.77%, it has a expensive valuation with a 3.04 Enterprise value to Capital Employed

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 25,634 Million (Mid Cap)

stock-summary
P/E

34.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.92%

stock-summary
Debt Equity

0.23

stock-summary
Return on Equity

10.77%

stock-summary
Price to Book

3.66

Revenue and Profits:
Net Sales:
1,391 Million
(Quarterly Results - Jun 2025)
Net Profit:
178 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.31%
0%
7.31%
6 Months
15.1%
0%
15.1%
1 Year
19.48%
0%
19.48%
2 Years
19.72%
0%
19.72%
3 Years
25.46%
0%
25.46%
4 Years
13.98%
0%
13.98%
5 Years
37.49%
0%
37.49%

STERIS Plc (Ireland) for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

STERIS Plc Experiences Valuation Adjustment Amid Competitive Market Landscape

STERIS Plc Experiences Valuation Adjustment Amid Competitive Market Landscape

STERIS Plc, a midcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation metrics, with a P/E ratio of 34 and a price-to-book value of 3.63. The company has experienced a year-to-date return of 14.66%, though it lags behind the S&P 500. Its dividend yield is 0.92%.

Read full news article

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
13.16%
EBIT Growth (5y)
12.29%
EBIT to Interest (avg)
9.63
Debt to EBITDA (avg)
1.94
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
0.60
Tax Ratio
23.19%
Dividend Payout Ratio
35.14%
Pledged Shares
0
Institutional Holding
97.90%
ROCE (avg)
9.57%
ROE (avg)
9.68%

Valuation key factors

Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
3.63
EV to EBIT
25.84
EV to EBITDA
17.51
EV to Capital Employed
3.04
EV to Sales
4.74
PEG Ratio
1.28
Dividend Yield
0.92%
ROCE (Latest)
11.77%
ROE (Latest)
10.82%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 145 Schemes (37.78%)

Foreign Institutions

Held by 298 Foreign Institutions (32.38%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 8.72% vs -0.39% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 27.23% vs 13.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,391.10",
          "val2": "1,279.50",
          "chgp": "8.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "368.10",
          "val2": "354.60",
          "chgp": "3.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "15.90",
          "val2": "30.40",
          "chgp": "-47.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.80",
          "val2": "-56.50",
          "chgp": "95.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "178.00",
          "val2": "139.90",
          "chgp": "27.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "178.80%",
          "val2": "189.10%",
          "chgp": "-1.03%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 6.24% vs 3.65% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 10.54% vs 422.97% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,459.50",
          "val2": "5,138.70",
          "chgp": "6.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,462.70",
          "val2": "1,473.10",
          "chgp": "-0.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "86.30",
          "val2": "144.40",
          "chgp": "-40.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-119.00",
          "val2": "-69.80",
          "chgp": "-70.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "611.60",
          "val2": "553.30",
          "chgp": "10.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "180.70%",
          "val2": "176.70%",
          "chgp": "0.40%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary

Jun'25
Jun'24
Change(%)
Net Sales
1,391.10
1,279.50
8.72%
Operating Profit (PBDIT) excl Other Income
368.10
354.60
3.81%
Interest
15.90
30.40
-47.70%
Exceptional Items
-2.80
-56.50
95.04%
Consolidate Net Profit
178.00
139.90
27.23%
Operating Profit Margin (Excl OI)
178.80%
189.10%
-1.03%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 8.72% vs -0.39% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 27.23% vs 13.00% in Jun 2024

All Quarterly Resultsstock-summary

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
5,459.50
5,138.70
6.24%
Operating Profit (PBDIT) excl Other Income
1,462.70
1,473.10
-0.71%
Interest
86.30
144.40
-40.24%
Exceptional Items
-119.00
-69.80
-70.49%
Consolidate Net Profit
611.60
553.30
10.54%
Operating Profit Margin (Excl OI)
180.70%
176.70%
0.40%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 6.24% vs 3.65% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 10.54% vs 422.97% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About STERIS Plc (Ireland) stock-summary
stock-summary
STERIS Plc (Ireland)
Pharmaceuticals & Biotechnology
Steris plc, formerly Steris Ltd, is a provider of infection prevention and other procedural products and services. The Company offers a mix of capital equipment products, such as sterilizers and washers, surgical tables, lights and equipment management systems and connectivity solutions, such as operating room integration; consumable products, such as detergents and gastrointestinal endoscopy accessories and other products; services, including equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory services and outsourced reprocessing. The Company operates through four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. It’s Corporate and other segment includes the Defense and Industrial business unit. The Company serves the customers in the United Kingdom, the United States and many other countries throughout the world.
Company Coordinates stock-summary
Company Details
Block a Riverside IV, 70 Sir John Rogerson's Quay DUBLIN None : 2
stock-summary
Tel: 353 1 23220001 440 3927245
stock-summary
https://www.steris.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."